Dr Reddy’s Share Price Hit 52-Week High, Rise Over 4% Ahead of Q1 FY26 Results, Dividend

Dr Reddy’s Laboratories share price (NSE: DRREDDY) gained more than 4% on June 29, 2026, reaching a new 52-week high of ₹1,410. The stock came close to its all-time high of ₹1,413, recorded in August 2024. The rally was supported by strong buying interest, with the stock extending its gains for the sixth consecutive trading session. During this period, the share price has risen by more than 11%. 

USFDA Inspection at Hyderabad Facility 

Last week, Dr Reddy’s informed the stock exchanges that the US Food and Drug Administration (USFDA) completed a Pre-License Inspection (PLI) of its biologics manufacturing facility in Bachupally, Hyderabad. The inspection was conducted between June 16 and June 25, 2026. 

Following the inspection, the USFDA issued a Form 483 containing 7 observations. The company stated that it will address all the observations within the prescribed timeline. It also noted that this inspection is part of the ongoing regulatory review process and follows previous inspections conducted in 2023 and 2025. 

Upcoming Dividend and Quarterly Results 

Dr Reddy’s has announced a final dividend of ₹8 per share. Shareholders whose names appear in the company's records on the record date of July 10, 2026, will be eligible to receive the dividend. 

The company is also scheduled to announce its financial results for the quarter ended June 30, 2026, on July 22, 2026. The board will consider and approve both the standalone and consolidated unaudited financial results during the meeting. 

Launch of Bosutinib Tablets in the US 

Earlier this month, Dr Reddy’s launched Bosutinib Tablets 400 mg in the United States. The product is the first generic version of Bosulif available in the US market, strengthening the company's oncology portfolio. 

The company partnered with MSN Laboratories Private Limited for this product. Under the agreement, MSN is responsible for the product's development and manufacturing, while Dr Reddy’s holds the exclusive marketing rights in the United States. 

According to industry sales data, the branded version of Bosulif (400 mg) recorded approximately US$253.8 million in sales during the 12 months ended April 2026, highlighting the market opportunity for the newly launched generic medicine. 

Read more: Best Gold Stocks in June 2026 Based on 5‑Year CAGR: Sky Gold and Diamonds, Laxmi Goldorna House and More. 

Conclusion 

Dr Reddy’s Laboratories continued its strong upward momentum, with the stock hitting a fresh 52-week high on heavy trading volumes. While the company recently received 7 observations from the USFDA following an inspection of its Hyderabad biologics facility, it has committed to addressing them promptly.  

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.